Aerie Pharmaceuticals, Inc.
Symbol: AERI
NASDAQ
15.25
USDMarket price today
-9.4457
P/E Ratio
0.2147
PEG Ratio
753.62M
MRK Cap
- 0.00%
DIV Yield
Aerie Pharmaceuticals, Inc. (AERI) Stock Split, History Data
Working capital analysis
In terms of working capital, Aerie Pharmaceuticals, Inc. maintains a healthy position. The total current assets of the company are valued at $355650000. This represents a growth rate of 7.203% compared to the previous year. Breaking down the current assets, the cash and investments are worth $37187000, exhibiting a growth rate of -75.465% year-on-year. The receivables, another significant portion of the current assets, are valued at $158828000. The year-on-year growth rate for receivables is 183.510%. The inventory, which forms a critical part of the assets, is valued at $40410000. This represents a healthy year-on-year growth of 49.340% On the liabilities side, the company's current liabilities total $124991000. This reflects a growth rate of 19.641% over the previous year, indicating the company's financial obligations are well under control.
2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
---|---|---|---|---|---|---|
Cash and investments | 37.19 | 151.57 | ||||
Receavebles | 158.83 | 56.02 | ||||
Inventory | 40.41 | 27.06 | ||||
Other | 16.61 | 8.31 | ||||
Total Current Assets | 355.65 | 331.75 | ||||
Acc Payable | 8.29 | 8.83 | ||||
Short Term Debt | 4.37 | 4.92 | ||||
Other Current Liab | 48.03 | 39.87 | ||||
Current Liabilities | 124.99 | 104.47 |
Capital Structure
When examining the capital structure of Aerie Pharmaceuticals, Inc., it is clear that the company manages a robust portfolio. The value of their total assets clocks in at $375590000. When juxtaposed with the previous year, this marks a growth rate of 6.762%, showcasing the company's ability to steadily grow its asset base. Turning to liabilities, the company has total liabilities amounting to $539572000. Compared to the prior year, this reflects a growth rate of 27.054%. The long-term debt forms a sizable part of these liabilities, coming in at $332113000. Over the last year, the long-term debt has grown by 32.482%. On the asset side, the cash and equivalent reserves are worth $54093000. The year-on-year growth of these reserves is -12.537%. The company's common stock, another important asset, holds a value of $49000, growing at a rate of 4.255% from the previous year. Finally, the company's retained earnings stand at $-1188037000, marking a growth rate of -0.951% year-over-year. These earnings represent the profits that Aerie Pharmaceuticals, Inc. has chosen to reinvest in the business rather than distribute as dividends.
Total Assets
$375.59
Total liabilities
$539,572,000.00
Long term debt
$332.11
Cash and eqv
$54,093,000.00
Goodwill
$0.00
Retained earnings
-$1,188,037,000.00
Common stock
$0.01
Enterprise Value
$28.60
Net earnings per share (EPS)
Aerie Pharmaceuticals, Inc. has an EPS of $-1.73, which signifies the profit allocated per share of common stock. With a growth rate of -6.135% this year, it indicates the company's increasing profitability and potential for share value growth. This trend signals robust financial performance and future potential.
Years | Q1 | Q2 | Q3 | Q4 | Total |
---|---|---|---|---|---|
2022 | -0.76 | -0.41 | -0.56 | - | -1.73 |
2021 | -0.91 | -0.84 | -0.86 | 0.98 | -1.63 |
2020 | -1.07 | -1.05 | -0.86 | -1 | -3.98 |
2019 | -1.06 | -1.04 | -1.09 | -1.21 | -4.40 |
2018 | -1.05 | -1.4 | -1.96 | -1.14 | -5.55 |
2017 | -0.76 | -0.82 | -0.89 | -1.6 | -4.07 |
2016 | -0.85 | -0.87 | -0.81 | -0.87 | -3.40 |
2015 | -0.7 | -0.73 | -0.69 | -0.77 | -2.89 |
2014 | -0.28 | -0.49 | -0.54 | -0.68 | -1.99 |
2013 | -0.24 | -0.4 | -0.48 | -0.61 | -1.73 |
2012 | - | - | -0.23 | -0.22 | -0.45 |
Frequently Asked Question
What is the latest historical split date of the company?
The latest historical split date is N/A.
What is firm free cah flow per share (FCF per share)?
The free cah flow per share (FCF per share) is -2.211.
What is company revenue per share?
The company revenue per share is -0.233.
What are firm earnings per share?
The firm earnings per share is 1.008.
What is Aerie Pharmaceuticals, Inc. (AERI) ROIC (return on capital)?
Aerie Pharmaceuticals, Inc. (AERI) ROIC (return on capital) is -0.148.
What is dividend per share figure?
The dividend per share is 0.000
What is enterprise plowback ratio?
Aerie Pharmaceuticals, Inc. (AERI) plowback ratio is N/A
What is firm enterprise value (EV)?
The enterprise value (EV) is 28.601
What is company debt to equity ratio?
The debt to equity ratio is -15.037
What are debt ratio numbers?
The debt ratio is 0.604
What is company price to sales ratio?
The price to sales ratio is 0.000